The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years. “Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.” The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs. It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval. |
Supreme Court to hear arguments over mifepristone TuesdayGovernment increases support for Ukraine, extends NZDF deploymentSMU suspends football player named in highPaurova becomes eighth Oregon State player to enter the portalAnonymous accounts use rightBiden looks to nudge further ahead with Alaska and Wyoming Democratic delegatesTom Watson wants the unity he saw at Masters Champions Dinner for all of golf, end to PGAHow a Black conservative activist arranged Donald Trump's stop at an Atlanta ChickTrump's hush money trial: What to know with jury selection to begin MondayBoston Red Sox shortstop Trevor Story has season